
Analgesics Market Report 2026
Global Outlook – By Type (Non-opioids, Opioids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores), By Application (Internal Analgesics, External Analgesics) – Market Size, Trends, Strategies, and Forecast to 2035
Analgesics Market Overview
• Analgesics market size has reached to $113.1 billion in 2025 • Expected to grow to $132.6 billion in 2030 at a compound annual growth rate (CAGR) of 3.4% • Growth Driver: Increasing Healthcare Expenditures Boosting The Analgesics Market • Market Trend: Market Shift Towards Combination Analgesics: Hikma Pharmaceuticals Launches Combogesic Iv • North America was the largest region in 2025 and Middle East is the fastest growing region.What Is Covered Under Analgesics Market?
Analgesics are the pain killers that are used to treat mild or severe pain, including musculoskeletal pain, surgical, trauma pain, cancer pain, or another type of pain. Examples of analgesics include codeine, hydrocodone, oxycodone, and methadone. The different types of analgesics are non-opioids and opioids. Non-opioid analgesics are pain relievers available over-the-counter (OTC) and by prescription. They are rapidly being promoted as a desirable, safe, and productive first-line therapeutic alternative to opioid drugs in a range of clinical settings for mild to severe acute and chronic pain. The different types of drugs include prescription analgesics, and OTC analgesics and involve various routes of administration, such as oral, intravenous, rectal, transdermal, and topical. It is used in internal analgesics, and external analgesics and distributed through various channels, such as hospital pharmacies, retail pharmacies, and drug stores.
What Is The Analgesics Market Size and Share 2026?
The analgesics market size has grown steadily in recent years. It will grow from $113.1 billion in 2025 to $115.82 billion in 2026 at a compound annual growth rate (CAGR) of 2.4%. The growth in the historic period can be attributed to rise in global musculoskeletal disorders, increase in surgical procedures, growing cancer incidence, expansion of hospital infrastructure, widespread availability of generic analgesics.What Is The Analgesics Market Growth Forecast?
The analgesics market size is expected to see steady growth in the next few years. It will grow to $132.6 billion in 2030 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to advancements in personalized medicine, increased r&d in opioid alternatives, growth of e-pharmacies and digital healthcare, rising geriatric population, adoption of smart manufacturing in pharma. Major trends in the forecast period include personalized pain management solutions, growth in opioid and non-opioid drug development, expansion of hospital and retail pharmacy channels, increase in chronic pain and cancer pain treatment demand, rising awareness of safe analgesic usage.Global Analgesics Market Segmentation
1) By Type: Non-opioids, Opioids 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores 3) By Application: Internal Analgesics, External Analgesics Subsegments: 1) By Non-Opioids: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol), Salicylates 2) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic OpioidsWhat Is The Driver Of The Analgesics Market?
The rise in healthcare expenditures is expected to propel the growth of the analgesics market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. A rise in healthcare expenditure drives research and development in the pharmaceutical industry for new and improved analgesic drugs. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare spending rose by 5.6% in nominal terms from 2022 to 2023. Therefore, the rise in healthcare expenditures is driving the growth of the analgesics industry.Key Players In The Global Analgesics Market
Major companies operating in the analgesics market are Pfizer Inc., Johnson & Johnson Services Inc., Medley Pharmaceuticals Limited, AbbVie Inc., Bayer HealthCare Pharmaceuticals LLC, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca Plc., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical company Limited, Eli Lilly and Company, Reckitt Benckiser Group plc, Viatris Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Limited, Purdue Pharma L.P, Cipla Limited, Allergan Inc., Endo International plc, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals Ltd., Chattem Inc., Hisamitsu Pharmaceutical Co.Inc., GW Pharmaceuticals, Verve Health Care Ltd., Alder BioPharmaceuticals Inc., Achelios Therapeutics Inc., WEX Pharmaceuticals Inc., Zynerba Pharmaceuticals, McNeil Consumer & Specialty Medical Products, Innovative Med Concepts LLCGlobal Analgesics Market Trends and Insights
Major companies operating in the analgesic market are increasing their focus on introducing combination analgesics to gain a competitive edge in the market. Combination analgesics are medications that contain a mixture of two or more different pain-relieving (analgesic) drugs. These combinations are often formulated to provide more effective pain relief by targeting pain through multiple mechanisms. For instance, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched COMBOGESIC IV (acetaminophen and ibuprofen) in the United States. COMBOGESIC IV is an intravenous formulation that combines acetaminophen (paracetamol) and ibuprofen, offering dual-action pain relief by leveraging the analgesic and anti-inflammatory properties of both drugs. Designed as a new non-opioid option for pain management, this intravenous formulation delivers 1,000 mg of acetaminophen and 300 mg of ibuprofen, offering an effective alternative amid rising concerns over opioid use. COMBOGESIC IV delivers over twice the pain relief of its individual components, with a faster onset and a favorable safety profile.What Are Latest Mergers And Acquisitions In The Analgesics Market?
In December 2023, Wellnex Life Limited, an Australian company specializing in the health and wellness sector, acquired Pain Away Ltd. for $22 million. This acquisition is a transformative move for Wellnex, aligning with its long-term strategy to own brands in defensive healthcare segments and enhancing its competitive position in the market. Pain Away Ltd. is a US-based company focused on developing and distributing topical pain relief products.Regional Insights
North America was the largest region in the analgesics market in 2025. Middle East is expected to be the fastest-growing region in the global analgesics market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Analgesics Market?
The analgesics market consists of sales of codeine, hydrocodone, oxycodone, and methadone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Analgesics Market Report 2026?
The analgesics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the analgesics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Analgesics Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $115.82 billion |
| Revenue Forecast In 2035 | $132.6 billion |
| Growth Rate | CAGR of 2.4% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Type, Distribution Channel, Application |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Pfizer Inc., Johnson & Johnson Services Inc., Medley Pharmaceuticals Limited, AbbVie Inc., Bayer HealthCare Pharmaceuticals LLC, Novartis International AG, Sanofi SA, Bristol-Myers Squibb Co., AstraZeneca Plc., Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical company Limited, Eli Lilly and Company, Reckitt Benckiser Group plc, Viatris Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Limited, Purdue Pharma L.P, Cipla Limited, Allergan Inc., Endo International plc, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals Ltd., Chattem Inc., Hisamitsu Pharmaceutical Co.Inc., GW Pharmaceuticals, Verve Health Care Ltd., Alder BioPharmaceuticals Inc., Achelios Therapeutics Inc., WEX Pharmaceuticals Inc., Zynerba Pharmaceuticals, McNeil Consumer & Specialty Medical Products, Innovative Med Concepts LLC |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
